Abstract: Compounds referred to herein as oligonucleotide clamps are provided that stably bind to target polynucleotides in a sequence-specific manner. The oligonucleotide clamps comprise one or more oligonucleotide moieties capable of specifically binding to a target polynucleotide and one or more pairs of binding moieties covalently linked to the oligonudeotide moieties. In accordance with the invention, upon annealing of the oligonucleotide moieties to the target polynucleotide, the binding moieties of a pair are brought into juxtaposition so that they form a stable covalent or non-covalent inkage or complex. The interaction of the binding moieties of the one or more pairs effectively clamps the specifically annealed oligonucleotide moieties to the target polynucleotide.
Abstract: A reverse transcriptase assay is described. A modular nanostructure comprising relatively small and relatively long RNA sequences is utilized in the assay.
Abstract: A computational method maximizing open reading frame length in an assembly consensus sequence is provided. Systems employing the method are also provided.
Abstract: The invention provides GlmU polypeptides and polynucleotides encoding GlmU polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing GlmU polypeptides to screen for antibacterial compounds.
Type:
Grant
Filed:
November 17, 1997
Date of Patent:
March 28, 2000
Assignee:
SmithKline Beecham Corporation
Inventors:
Christine DeBouck, Deborah Dee Jaworski, Jeffrey L Mooney, Lisa Kathleen Shilling, Nicola Gail Wallis, Min Wang, Yi Yi Zhong
Abstract: A process and apparatus for cell purification and ablation is disclosed. The present invention comprises a laser system which directs radiant energy at computer or manually selected individual cells thereby disrupting DNA, RNA and protein structure in those cells. The present invention produces a purified tissue section containing relatively intact DNA, RNA or protein from only the untreated cells. This purified sample is suitable for amplification of material by PCR or other techniques for the analysis of molecular genetic features in the selected cells of interest.
Abstract: Double stranded nucleic acid is denatured by subjecting a solution thereof to a voltage applied between electrodes spaced by no more than 1.5 mm in a time not previously achievable in electrochemical denaturation. PCR is practiced isothermally by periodic application of voltage to produce denaturation. Electrochemical cells and kits for use in the process are provided.
Abstract: An assay for systemic lupus erythematosus based upon capture of the anti-dsDNA portion of IgG in a human serum specimen by the Fc part of a molecule using solid phase immobilized F(ab')2 fragment of anti-human IgG specific for Fc, the captured IgG being then incubated with a synthetic dsDNA tagged with a moiety from which a signal proportional to the quantity of said synthetic dsDNA can be elicited. Upon eliciting a signal from the moiety, the amount of antibody to dsDNA can be quantified, providing diagnostic and prognostic information regarding the disease.
Abstract: Disclosed is a process for identifying clones having a specified enzyme activity by screening for the specified enzyme activity in a library of clones prepared by (i) selectively isolating target nucleic acid from nucleic acid derived from at least one microorganism, by use of at least one polynucleotide probe comprising at least a portion of a nucleic acid sequence encoding an enzyme having the specified enzyme activity; and (ii) transforming a host with isolated target nucleic acid to produce a library of clones which are screened for the specified enzyme activity.
Abstract: A method is disclosed for extending a primer to produce a single stranded polydeoxynucleotide that has two or more defined sequences. A combination is provided which comprises a template polynucleotide, a blocker polynucleotide, a primer polynucleotide and a polynucleotide Q. The template polynucleotide has three sequences T1, T2 and T3 wherein T1 is non-contiguous and 3' of T3 and wherein the 5' end of T3 is 5' of the 5' end of T2. The primer polynucleotide has a second defined sequence at its 3' end that is hybridizable with T1. The blocker polynucleotide has sequence B1 that is hybridizable with T3. Polynucleotide Q has sequences S1 and S2 wherein S1 is 3' of S2 and homologous with T2 and S2 is complementary to a first defined sequence that is to be introduced at the 3' end of the polynucleotide primer, when it is extended during the method of the invention. Polynucleotide Q is either attached to the 5' end of the blocker polynucleotide or present as a separate reagent.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
February 29, 2000
Assignee:
Behring Diagnostics GmbH
Inventors:
Maureen Laney, Yan Chen, Edwin F. Ullman, Karen M. Hahnenberger
Abstract: Fluorescent labels having at least one donor and at least one acceptor fluorophore bonded to a polymeric backbone in energy transfer relationship, as well as methods for their use, are provided. Of particular interest are the subject labels wherein the polymeric backbone is a nucleic acid and the donor fluorophore is bonded to the 5' terminus of said nucleic acid. Such labels find use as primers in applications involving nucleic acid chain extension, such as sequencing, PCR and the like.
Type:
Grant
Filed:
May 8, 1996
Date of Patent:
February 22, 2000
Assignee:
The Regents of the University of California
Inventors:
Richard Mathies, Alexander Glazer, Jingyue Ju
Abstract: Human pancreatic islet cell glutamic acid decarboxylase (GAD), an autoantigen involved in the development of insulin-dependent diabetes mellitus (IDDM), has been cloned, sequenced and expressed by recombinant means. Recombinant human islet cell GAD polypeptides and antibodies specific to the GAD polypeptides can be used in methods of diagnosis and treatment, including use in immunoadsorptive therapy and the induction of immune tolerance.
Type:
Grant
Filed:
May 30, 1995
Date of Patent:
February 15, 2000
Assignee:
The Board of Regents of the University of Washington and ZymoGenetics, Inc.
Inventors:
Ake Lernmark, Allan E. Karlsen, Catherine E. Grubin, William Hagopian, Patrick J. O'Hara, Donald C. Foster
Abstract: The present invention is a method for ranking the affinity of each of a multiplicity of different molecules for a target molecule which is capable of denaturing due to a thermal change. The method comprises contacting the target molecule with one molecule of the multiplicity of different molecules in each of a multiplicity of containers, simultaneously heating the multiplicity of containers, measuring in each of the containers a physical change associated with the thermal denaturation of the target molecule resulting from the heating in each of the containers, generating a thermal denaturation curve for the target molecule as a function of temperature for each of the containers and determining a midpoint temperature (T.sub.m) therefrom, comparing the T.sub.m of each of the thermal denaturation curves with the T.sub.
Type:
Grant
Filed:
May 9, 1997
Date of Patent:
February 1, 2000
Assignee:
3-Dimensional Pharmaceuticals, Inc.
Inventors:
Michael W. Pantoliano, Alexander W. Rhind, Francis R. Salemme
Abstract: The present invention relates to a novel enzyme which is derived from bacterial cells of a strain belonging to the genus Pseudomonas fluorescens and which catalyzes a reaction for oxidizing substrates such as p-hydroxytoluene derivatives and p-alkylphenol derivatives as well as a method for preparing, for instance, 3-(p-hydroxyphenyl)-2-propenol derivatives, p-hydroxybenzaldehyde derivatives, p-alkylphenol derivatives and optically active S(-)-1-(4-hydroxyphenyl) alcohol derivatives, using the enzyme.
Abstract: A signal processing method in a processor is provided for performing a multicomponent analysis of a signal resulting from a spectral response of a mixture comprising a plurality of spectrally resolvable molecular species. The method provides both a determination of a concentration estimate and a statistical confidence interval for each species. In the method, a data vector d is received from a multichannel detector, data vector d having a length n.sub.c, n.sub.c being the number of detector channels being monitored. A calibration matrix K having n.sub.c rows and n.sub.p columns is provided wherein n.sub.c is larger than n.sub.p, n.sub.p being the number of spectrally resolvable molecular species. Next, a concentration estimate vector c having length n.sub.p is determined. Finally, a confidence interval CI.sub.i for each of the elements of the concentration estimate vector is determined according to the expressionCI.sub.i =c.sub.i .+-.(varcovar(c.sub.ii)).sup.1/2 Q.sub.
Abstract: The present invention concerns the field of molecular genetics and medicine. Particularly, it concerns a gene, FXI-T1, whose mRNA levels are increased in fractionated X-irradiation induced leukemias and methods of using FXI-T1 to classify tissue samples for medical purposes. Specifically, the invention concerns the murine and human homologs of FXI-T1.
Abstract: The invention relates to the detection of apoptotic cells using a novel assay that employs ligation of DNA fragments in situ to selectively label apoptotic cells. The assay may be used in combination with known in situ methodologies to simultaneously detect apoptotic cells and specific biomolecules present in the apoptotic cell.
Abstract: The present invention provides polynucleotide and polypeptide molecules for a novel human prohormone convertase 4. The polynucleotides encoding human prohormone convertase 4, are located on chromosome 19, and may, for example, be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein and antibodies thereto.
Abstract: A direct quantitation of RNA contained in a sample is obtained by capillary electrophoresis of the RNA hybridized to a DNA probe of complementary sequence stabilized by the combination of a fluorophore terminally conjugated to the DNA probe and a dye intercalating the RNA-DNA hybrid so formed. The RNA is quantified by measuring the total fluorescence emitted by the electrophoresed hybrid upon excitation by a laser generated light beam.
Abstract: The invention provides a method of nucleic acid sequence analysis based on the ligation of one or more sets of encoded adaptors to the terminus of a target polynucleotide. Encoded adaptors whose protruding strands form perfectly matched duplexes with the complementary protruding strands of the target polynucleotide are ligated, and the identity of the nucleotides in the protruding strands is determined by an oligonucleotide tag carried by the encoded adaptor. Such determination, or "decoding" is carried out by specifically hybridizing a labeled tag complement to its corresponding tag on the ligated adaptor.
Type:
Grant
Filed:
October 7, 1997
Date of Patent:
January 11, 2000
Assignee:
Lynx Therapeutics, Inc.
Inventors:
Glenn Albrecht, Sydney Brenner, Robert B. DuBridge, David H. Lloyd, Michael C. Pallas
Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel pancreas-derived serpin (PDS) expressed in human pancreas. The present invention also provides for antisense molecules to the nucleotide sequences which encode PDS, expression vectors for the production of purified PDS, antibodies capable of binding specifically to PDS, hybridization probes or oligonucleotides for the detection of PDS-encoding nucleotide sequences, genetically engineered host cells for the expression of PDS, diagnostic tests based on PDS-encoding nucleic acid molecules and a pharmaceutical composition containing PDS capable of binding specifically to a serine protease.
Type:
Grant
Filed:
November 25, 1997
Date of Patent:
January 11, 2000
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Scott Michael Braxton, Craig G. Wilde, Dinh Diep